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Abstract
Introduction We hypothesized that the use of intrapulmonary
percussive ventilation (IPV), a technique designed to improve
mucus clearance, could prove effective in avoiding further
deterioration in patients with acute exacerbations of chronic
obstructive pulmonary disease (COPD) with mild respiratory
acidosis.
Methods The study was performed in a medical intensive care
unit of a university hospital. Thirty-three patients with
exacerbations of COPD with a respiratory frequency ≥  25/min,
a PaCO2 > 45 Torr and 7.35 ≤  pH ≤  7.38 were included in the
study. Patients were randomly assigned to receive either
standard treatment (control group) or standard treatment plus
IPV (IPV group). The IPV group underwent two daily sessions of
30 minutes performed by a chest physiotherapist through a full
face mask. The therapy was considered successful when both
worsening of the exacerbation and a decrease in pH to under
7.35, which would have required non-invasive ventilation, were
avoided.
Results Thirty minutes of IPV led to a significant decrease in
respiratory rate, an increase in PaO2 and a decrease in PaCO2
(p < 0.05). Exacerbation worsened in 6 out of 17 patients in the
control group versus 0 out of 16 in the IPV group (p < 0.05). The
hospital stay was significantly shorter in the IPV group than in
the control group (6.8 ± 1.0 vs. 7.9 ± 1.3 days, p < 0.05).
Conclusion IPV is a safe technique and may prevent further
deterioration in patients with acute exacerbations of COPD with
mild respiratory acidosis.
Introduction
Acute exacerbations of chronic obstructive pulmonary disease
(COPD) are a frequent cause of admission to hospital and the
intensive care unit (ICU) [1]. Despite a well conducted medical
treatment, worsening can occur in patients with acute exacer-
bations of COPD and lead to a decompensation phase. Acute
respiratory failure can lead to the requirement of mechanical
ventilation; in these cases, non-invasive ventilation (NIV) must
be considered in order to avoid invasive mechanical ventilation
and its related complications [2-4]. Studies by Plant et al. [4]
offer very strong arguments for the delivery of NIV as soon as
the patient develops an increase in PaCO2 and respiratory aci-
dosis. Numerous patients are hospitalized with mild respira-
tory acidosis. Airway inflammation, bronchospasm and the
increase in sputum volume are constant in these patients and
are responsible for an increase in airway resistance and air
trapping [5]. This air trapping and increased airway resistance
result in hyperinflation and intrinsic positive expiratory pres-
sure (PEEPi), which are common features during acute exac-
erbations of COPD patients and are responsible for increasing
the work required to breathe and respiratory muscle failure.
Methods of treatment directed against the onset of
COPD = chronic obstructive pulmonary disease; CPAP = continuous positive airway pressure; FEV1 = forced expiratory volume in one second; HFO 
= high frequency oscillatory ventilation; ICU = intensive care unit; IPV = intrapulmonary percussive ventilation; NIV = non-invasive ventilation; PEEPi 
= intrinsic positive expiratory pressure; PEEP = positive end-expiratory pressure; RR = respiratory rate; SAPS II = simplified acute physiologic score; 
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decompensation are attractive in theory, although the benefits
of mucus clearance therapies have been regularly challenged
[6-10]. Nevertheless, in COPD patients, there is a pathophys-
iological rationale for the use of a mucus clearance therapy.
Hypersecretion of mucus, changes in mucus viscoelasticity
and surface adhesion, and impaired ciliary function lead to
entrapped mucus. Retained airway secretions can form mucus
plugs and bronchial casts that cannot be expelled by cough-
ing. Airway plugging causes impaired ventilation, resulting in
lower ventilation-to-perfusion ratios. Increased airway resist-
ance to airflow and air trapping result in hyperinflation of the
chest and inspiratory loading of the respiratory muscles, lead-
ing to fatigue [11-14]. Two studies have shown that chest
physiotherapy based on a mucus clearance strategy could
represent a useful therapeutic option in exacerbations of
patients with COPD [15,16].
Intrapulmonary percussive ventilation (IPV), intended for the
therapeutic mobilization of bronchial secretions, has been pri-
marily used in patients with cystic fibrosis in a stable state [17-
22]. In addition, small pilot studies have shown the IPV device
to be useful for increasing sputum production in patients with
COPD [23,24]. IPV could offer a treatment directed against
the onset of decompensation, specifically the increase in air-
way mucus that is responsible for increasing airway
resistance.
We hypothesized that the use of IPV could be effective in
avoiding further deterioration in patients admitted with acute
exacerbations of COPD. In this prospective, randomized, con-
trolled study, we compared the efficacy of standard medical
treatment with supplemental oxygen and no ventilatory sup-
port to standard medical treatment with supplemental oxygen
plus IPV in patients with acute exacerbations of COPD.
Materials and methods
Patients
Adult patients hospitalized in our ICU due to an acute exacer-
bation of COPD were prospectively studied. The experimental
protocol was approved by the institutional review board of the
hospital, and all patients or their next of kin provided written
informed consent.
Inclusion and exclusion criteria
Patients were eligible for the study if they were admitted as an
emergency with an exacerbation of COPD (on the basis of the
clinical history, physical examination, and chest radiograph)
[25], and a respiratory rate (RR) ≥  25/min, PaCO2 > 45 Torr
after the patient had been breathing room air for at least 10
minutes, and 7.35 ≤  pH ≤  7.38 without metabolic acidosis.
Exclusion criteria were: the requirement for emergency intuba-
tion for cardiopulmonary resuscitation, respiratory arrest, or in
the case of rapid deterioration in neurological status (Glasgow
coma scale [26] of ≤  8); hemodynamic instability defined as a
systolic blood pressure of less than 80 mmHg or evidence on
electrocardiography of ischemia or clinically significant ven-
tricular arrhythmias; failure of more than two additional organs;
or tracheotomy, pneumothorax, facial deformity, or a recent
history of oral, oesophageal or gastric surgery. Patients were
randomly assigned to receive standard treatment or standard
treatment plus IPV through a face mask. Random assignments
were made with sealed envelopes.
Monitoring
Arterial oxygen saturation was monitored continuously with a
bedside pulse oximeter (Oxisensor, Nellcor, Hayward, CA,
USA); heart rate and RR were displayed on the screen of the
monitor.
Standard treatment
Patients assigned to standard treatment received oxygen with
nasal cannulae to maintain a target oxygen saturation
(recorded by pulse oximetry) of 88% to 92%. In all patients,
the heart rate and RR were monitored continuously. The head
of the bed was kept elevated at a 45-degree angle. The stand-
ard drug protocol consisted of nebulised salbutamol (5 mg
every 4 h) or terbutaline, nebulised ipratropium bromide (500
µg every 6 h), subcutaneous heparin, corticosteroids (methyl
prednisolone 2 mg/kg of body weight intravenously per day for
three days; then decreasing doses of oral methyl prednisolone
for 15 days), and an antibiotic [27]. Medication included the
correction of electrolyte abnormalities.
Intrapulmonary percussive ventilation
The IPV device was developed by Forrest M. Bird in 1979 (Fig.
1). IPV is a ventilatory technique that delivers small bursts of
high flow respiratory gas into the lung at high rates. This
causes airway pressures to oscillate between 5 and 35
cmH2O and the airway walls vibrate in synchrony with these
oscillations. A unique sliding venturi called a phasitron (Fig. 2)
is powered by compressed gas at 25 to 40 pounds per square
inch and generates these oscillations in the range of 80 to 650
cycles per minute [28]. During inspiration the high frequency
gas pulse expands the lungs and vibrates and enlarges the air-
ways. This technique may be associated with nebulization [29]
and has the potential to improve secretion clearance [30]. Dur-
ing the percussive bursts of air into the lungs, a continued
pressure is maintained, while a high velocity percussive inflow
opens airways and enhances intra-bronchial secretion
mobilization.
Patients assigned to the IPV group received the same medica-
tion as the patients in the standard-treatment group with the
addition of two sessions of IPV per day. No patient in either
group received externally applied treatments designed to clear
mucus. IPV sessions were performed by the specialized and
trained respiratory therapist and delivered to the patient
through a full face mask (La Cigogne, Pessac, France). The
mask was adjusted and connected to the intrapulmonary per-
cussive ventilator (IPV1 device, Percussionaire Corp.,Available online http://ccforum.com/content/9/4/R382
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Sandpoint, ID, USA). After the mask had been secured, the
percussions were delivered into the lungs of the patient. The
frequency of the percussion was initially set at 250/minute and
the peak pressure was initially set at 20 cmH2O. Frequency
and peak pressure were adjusted for each patient to improve
comfort and to be certain that the entire thorax was being per-
cussed; this was done on the basis of visualization of external
thoracic movements and perception of thrill on the patient's
thorax. The inspiration-to-expiration ratio was adjusted to 1/
2.5. During IPV sessions, the nebulizer delivered only NaCl
0.9%. Oxygen was fed into the mask to maintain oxygen satu-
ration between 88% and 92%. The duration of each IPV ses-
sion was 30 minutes. Between periods of IPV, patients
breathed oxygen spontaneously while arterial oxygen satura-
tion was continuously monitored. IPV sessions were stopped
when the patients reached a RR of < 25/min and a pH > 7.38
in spontaneous breathing without worsening for 24 h.
Success of therapy
Therapy was considered to be successful when it enabled the
avoidance of both a worsening of the exacerbation and a
decrease in pH to under 7.35 (which would have required
NIV), and allowed the patient to be discharged from the ICU.
Criteria for non-invasive ventilation
NIV was used as previously described [31,32] when patients
were tachypnoeic with a RR of more than 25/min and a respi-
ratory acidosis defined by a PaCO2 > 45 Torr and a pH lower
than 7.35 without metabolic acidosis, at any time during the
study.
Follow-up
The RR and arterial-blood gas levels were recorded at base
line and at the end of the first IPV session. On subsequent
days, these data were obtained once daily during the morning.
IPV session comfort was assessed using a five-point verbal-
rating scale (comfortable, mildly uncomfortable, moderately
uncomfortable, very uncomfortable, and intolerable). To
assess the patient's severity of illness on ICU admission Sim-
plified Acute Physiologic Score (SAPS II) was recorded for
each patient [33]. Pulmonary function data were obtained from
previous spirometric tests in 13 patients in the IPV group and
in 14 patients in the control group (the last test was retained).
For the other patients (three in the IPV group and three in the
control group), reliable pulmonary function data were obtained
within two months of inclusion in the study.
Hospital stay
Patients were discharged from the ICU when their pH was
higher than 7.38. Patients were discharged from the hospital
when their clinical status and gas exchange were comparable
to the stable state.
Statistical analysis
The primary outcome variable was the avoidance of a worsen-
ing of the acute exacerbation leading to decompensation,
defined by a pH < 7.35, and so the need for NIV at any time
during the study. The secondary end point was the length of
the hospital stay. Results are given as means ± standard devi-
ation (SD). The group means were compared with the t-test.
Repeated-measures analysis of variance was used to compare
the partial pressure of arterial oxygen, PaCO2, RR, and bicar-
bonate values measured at base line and at the end of the first
IPV session. A p-value of less than 0.05 was considered to
indicate statistical significance. Analyses were done using




A total of 81 patients who underwent episodes of acute exac-
erbation of COPD were admitted to our ICU over one 18
month period. Of these, 48 patients were excluded from the
Figure 1
The intrapulmonary percussive ventilation (IPV) device (Percussionaire  Corp., Sandpoint, ID, USA) and the full face mask used in the study The intrapulmonary percussive ventilation (IPV) device (Percussionaire 
Corp., Sandpoint, ID, USA) and the full face mask used in the study.Critical Care    Vol 9 No 4    Vargas et al.
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study: 40 patients required NIV because of a pH < 7.35
despite a well conducted medical treatment; and eight
patients required immediate endotracheal intubation. In the
end, 33 patients were included, of which 17 were randomly
assigned to standard treatment, and 16 to IPV. The two
groups had similar characteristics on admission (Table 1). The
patients in both groups had respiratory disease of a similar
severity; the functional steady-state characteristics were thus
similar in the two groups. The same was true for the severity of
exacerbation; there were also no significant differences in the
SAPS II and the arterial blood gas levels between the standard
treatment group and the IPV group. Chest X-ray findings were
similar between the two groups. Four patients in the standard
group and three patients in the IPV group had been previously
non-invasively ventilated for a similar episode. The same med-
ication was administered to the patients of both groups.
Clinical outcome
As shown in Table 2, 6 out of 17 patients (35.3%) in the con-
trol group progressed to the point of requiring NIV, compared
with 0 out of 16 in the IPV group (p < 0·05). The mean interval
between entry into the study and decompensation was 48 ±
12 h for the six patients of the control group. NIV was success-
Figure 2
Schematic of the phasitron Schematic of the phasitron. The sliding venturi body moves back and forth to open and close the phasitron exhalation gate by an orificed diaphragm. 
Burst of air and aerosol are delivered to the patient during forward movement of the phasitron.
Table 1
Characteristics of COPD patients assigned to receive intrapulmonary percussive ventilation or standard treatment at inclusion
IPV (n = 16) Standard treatment (n = 17) p-value
Age (years) 69.2 ± 6.0 70.2 ± 5.0 NS
SAPS II 25.4 ± 6.0 25.4 ± 4.0 NS
Hb (g/dl) 13.7 ± 1.3 14.0 ± 1.4 NS
HR (beats/min) 117 ± 16 115 ± 19 NS
RR (breaths/min) 36 ± 2 36 ± 3 NS
SBP (mmHg) 141 ± 15 143 ± 16 NS
pH 7.37 ± 0.01 7.37 ± 0.01 NS
PaCO2 (Torr) 57.6 ± 4.5 58.0 ± 3.0 NS
PaO2 (Torr)a 56.9 ± 3.0 56.7 ± 3.0 NS
Bicarbonate (mmol/l) 33 ± 3 33 ± 3 NS
FEV1 (%)b 39 ± 7 38 ± 8 NS
aPatients received oxygen with nasal cannulae to maintain a target oxygen saturation (recorded by pulse oximetry) of 88% to 92%. Mean oxygen 
flow was 2.0 ± 0.5 l/min and 2.0 ± 0.5 l/min in the IPV group and the control group, respectively (p = NS).
bFEV1 was obtained from previous spirometric tests in 13 patients in the IPV group and in 14 patients in the control group (the last test was 
retained). For the other patients (three in the IPV group and three in the control group), reliable pulmonary function data were obtained within two 
months of inclusion. FEV1, forced expiratory volume in one second; Hb, hemoglobin; HR, heart rate; IPV, intrapulmonary percussive ventilation; 
RR, respiratory rate; SAPS II, simplified acute physiologic score; SBP, systolic arterial blood pressure; NS, not statistically significant.Available online http://ccforum.com/content/9/4/R382
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ful every time and none of these six patients needed invasive
mechanical ventilation. No patient included in the study died.
Physiological outcomes
The values for the physiological variables in the IPV group on
inclusion and at the end of the first IPV session are given in
Table 3. IPV led to an improvement in PaO2, PaCO2 and RR (p
< 0.05). No statistical difference was observed concerning the
pH.
IPV group
Patients assigned to the IPV group were given this method of
treatment for a mean duration of 3 ± 1 days. The duration of
IPV was half an hour twice daily. The mean frequency of the
percussions was 250 ± 50 per minute. The mean peak pres-
sure was 20 ± 5 cmH2O. IPV sessions were well tolerated.
The median comfort score of IPV sessions was 2 (mildly
uncomfortable). As judged by the physiotherapist in charge of
the patient, mucus clearance was greatly improved by the
application of the IPV.
Hospital stay
The hospital stay was significantly longer in the group receiv-
ing standard treatment than in the group receiving IPV (7.9 ±
1.3 versus 6.8 ± 1 days, p < 0.05).
Discussion
In this randomized trial, the use of IPV helped avoid further
deterioration in patients admitted with acute exacerbation of
COPD and mild acidosis. When compared with the patients
who received standard treatment, the patients who received
IPV had a lower incidence of NIV use and a shorter duration of
hospital stay.
In acute exacerbations of COPD patients, NIV has profoundly
changed the management and outcome of these patients [2].
The results of several prospective randomized controlled stud-
ies on NIV favor an early use of ventilatory methods as soon as
the patient develops an increase in PaCO2 and respiratory aci-
dosis [2,4]. To our knowledge, however, the potential benefits
of NIV in COPD patients with mild respiratory acidosis have
not been studied. We hypothesized that the use of IPV could
be effective in avoiding further deterioration in this situation.
To date, few studies have been published on the use of IPV in
adult patients with pulmonary disease. IPV has been used pri-
marily, however, for the treatment of atelectasis and retained
secretions in patients in a stable state, as occurs in a wide vari-
ety of conditions, including cystic fibrosis and neuromuscular
disease [17-22]. Ravez et al. [23] studied the use of IPV in a
small group of adults with chronic bronchitis. They found that
total lung clearance of radioaerosol was enhanced with IPV
therapy, but it was unclear how much IPV stimulated cough
contributed to the observed benefit [23]. In addition, small
Table 2
Clinical outcome of COPD patients assigned to receive intrapulmonary percussive ventilation or standard treatment
IPV (n = 16) Standard treatment (n = 17) p-value
Worsening of exacerbation with pH < 7.35 
(NIV required) (%)
0 (0) 6 (35.3) <0.05
Hospital stay (days) 6.8 ± 1.0 7.9 ± 1.3 <0.05
Hospital death 0 0 -
Table 3
Values of arterial blood gas and respiratory rate
IPV (n = 16)
Inclusion Post IPV session p-value
Arterial pH 7.37 7.38 NS
PaCO2 (Torr) 57.6 ± 4.5 53.5 ± 2.3 <0.05
PaO2 (Torr)a 56.9 ± 3.0 61.0 ± 0.8 <0.05
RR (breaths/min) 36 ± 2 31 ± 2 <0.05
Measurements were taken at inclusion and at the end of the first intrapulmonary percussive ventilation session (post IPV session; in the thirtieth 
minute). aOxygen flow was not changed between both periods and was 2.0 ± 0.5 l/min. IPV, intrapulmonary percussive ventilation; RR, respiratory 
rate; NS, not statistically significant.Critical Care    Vol 9 No 4    Vargas et al.
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pilot studies with the IPV device have shown it to be useful for
the relief of lobar atelectasis and for increased sputum produc-
tion in patients with COPD [24].
In this study, the most important question is: how does IPV
improve the clinical status of patients with COPD?
IPV is a mucus clearance device
Inflammatory cells are abundant in the sputum of patients with
chronic mucus retention. These cells are able to release medi-
ators that can alter the secretion and clearance of mucus. The
end result is airway plugging, which causes bronchial obstruc-
tion resulting in atelectasis, impaired lung mechanics and gas
exchange. There is a physiopathological rationale for the use
of mucus clearance therapies because even small decreases
in airway resistance may be important to achieve recompensa-
tion [11-14]. The benefits of mucus clearance strategies using
physical and respiratory therapies, however, have been regu-
larly challenged [27]. Three randomized, controlled trials of
chest physiotherapy [6-8] and one observational study [9],
showed that mechanical percussion of the chest as applied by
physical or respiratory therapists was ineffective and perhaps
even detrimental in the treatment of patients with acute exac-
erbations of COPD. None of these randomized trials reported
any improvement in ventilatory function with respect to either
forced expiratory volume in one second (FEV1) or functional
vital capacity [6-8]. Furthermore, one trial described a signifi-
cantly lower FEV1 in patients who received chest percussion
therapy compared with controls [7]. No other adverse effects
were reported. Does the lack of evidence, however, mean that
there is a lack of benefit? Two studies have shown that chest
physiotherapy based on a mucus clearance strategy could
represent a useful therapeutic option in patients with exacer-
bations of COPD [15,16]. Bellone et al. [15] demonstrated
that chest physiotherapy using a positive expiratory pressure
mask in patients with mild acidosis (mean pH = 7.33) requiring
NIV with pressure support could produce benefits in sputum
clearance and could reduce the amount of time that the patient
requires NIV [15]. Wolkove et al. [16] reported significant
improvement in lung function after inhaled bronchodilator ther-
apy, and the prior use of a mucus clearance device, compared
to a sham mucus clearance device, improved the subsequent
bronchodilator response in patients with stable COPD [16].
The mucus clearance device used (flutter device), promotes
the clearance of sputum through the generation of low fre-
quency pressure waves [16]. Both the IPV and the flutter
device appeared equally effective in removing obstructing
secretions from airways [34,35]. In our study, mucus clear-
ance obtained by the application of IPV was judged greatly
improved by the physiotherapist in charge of the patient; how-
ever, we did not measure the quantity of expectoration in both
groups. Thus we can not conclude that IPV in addition to
standard treatment increased the elimination of mucus to a
significant increment.
IPV theoretically increases mean airway pressure
PEEPi has been identified in patients with exacerbations of
COPD because of severe airway obstruction [36-40]. In order
to initiate inspiratory airflow, the respiratory muscles must gen-
erate a negative pressure equal in magnitude to PEEPi. The
presence of PEEPi also implies dynamic hyperinflation, with
consequent worsening of thoracic wall geometry and muscle
length-tension relationships. This further increases the work-
load of muscles as their efficiency and mechanical advantage
are reduced. The application of positive end-expiratory pres-
sure (PEEP) at the airway opening should decrease the pres-
sure gradient between the mouth and alveoli at the end of
expiration and so reduce the inspiratory threshold load [38-
40]. During the percussive sessions, IPV maintains an intrapul-
monary pressure, which serves to stabilize airway patency.
Improvement may occur via the beneficial effects of this
intrapulmonary pressure, including the reduction of PEEPi and
the amount of work required to breathe, which may allow res-
piratory muscles to regain efficiency.
High frequency oscillatory ventilation like effects
Considering the effect of high frequency oscillatory (HFO)
ventilation on gas exchange and breathing pattern, one can
hypothesize similar effects with IPV. Indeed, any high fre-
quency ventilation is a positive pressure ventilation, which
would increase the airway pressure (Paw), induce a 'PEEP
effect' and thus improve oxygenation [41]. Two mechanisms
explain gas transport with respect to the clearance of CO2 dur-
ing HFO,: convection and molecular diffusion. HFO maximizes
CO2 removal primarily through facilitated diffusion [41]. The
theoretical increase of mean Paw observed with IPV, however,
is less important than the increase of Paw observed with HFO.
Similarly, the frequency in HFO, generally set below 5 Hz, is
more important than in IPV.
IPV and lung volume
Any high frequency ventilation induces a PEEP effect that can
increase lung volume. But according to the 'waterfall theory', if
PEEPi is the result of expiratory flow limitation, application of
extrinsic PEEP should decrease the pressure gradient
between the mouth and alveoli at the end of expiration. This
should be achieved without further hyperinflation. Several
studies in patients during acute exacerbations of COPD have
demonstrated this effect [36,38,39]. O'Donoghue et al. [40],
however, found that only high levels of continuous positive air-
way pressure (CPAP) reduce PEEPi and indices of muscle
effort in patients with severe but stable COPD, but only at the
expense of a substantial increase in lung volume.
IPV sessions were well tolerated by the patients. Except for
one episode of transient haemoptysis reported in a patient
with cystic fibrosis [18], no serious adverse effects of IPV have
been reported in previous studies [17-19]. All types of inter-
faces could be used to perform IPV sessions. On the basis of
our previous experience with NIV in patients with acute exac-Available online http://ccforum.com/content/9/4/R382
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erbations of COPD [31,32], we used a full face mask to per-
form IPV. This interface was well tolerated as most patients
found the interface comfortable or only mildly uncomfortable.
The hospital stay was significantly shorter in the group receiv-
ing IPV than in the group receiving standard treatment. This
result suggests that IPV may be a cost-saving measure. In
addition, IPV sessions could be performed in general respira-
tory wards in COPD patients with mild respiratory acidosis
and so could minimize the transfer of these patients to ICU.
Further studies are needed to test this hypothesis.
Our study has several limitations. It is impossible to eliminate
bias when a study cannot be blinded, so we have to be very
careful concerning the shorter duration of the hospital stay in
the IPV group. The study included only selected COPD
patients with acute exacerbations who were treated in a single
ICU. In the study, the control group didn't receive normal saline
by nebulizer. Hypertonic saline has the potential of a muco-
tropic agent by shielding the excess of fixed negative charges
that develop on mucins in airway disease [42]. Despite this,
pharmacological mucus clearance strategies have not been
demonstrated to shorten the course of treatment for patients
with acute exacerbations of COPD, although there is a possi-
bility that these agents improve symptoms [27]. Miro et al.
[43], in a descriptive study, showed the benefit of CPAP ses-
sions in seven COPD patients with acute hypercapnic respira-
tory failure in an attempt to avoid endothacheal intubation and
mechanical ventilation. Goldberg et al. [44] conclude that the
non-invasive application of CPAP to spontaneously breathing
patients with severe COPD in acute respiratory failure
decreases inspiratory effort and dyspnea while improving
breathing pattern. End-expiratory lung volume remained stable
at the lower levels of CPAP, with only modest increases at the
higher levels [44]. These patients were at a more severe stage
of decompensation. To our knowledge, there are no data con-
cerning the utility of CPAP in acute exacerbations of COPD
with mild respiratory acidosis. In a recent study, however,
O'Donoghue et al. [40] found that only high levels of CPAP
reduce PEEPi and indices of muscle effort in patients with
severe but stable COPD, but only at the expense of a substan-
tial increase in lung volume. It would be interesting, therefore,
to perform another study with a control group of patients using
CPAP to correct for lung volume change during intervention.
We have not evaluated the long term effect of IPV. Treatment
with IPV was stopped when patients reached a RR of < 25/
min and pH > 7.38 in spontaneous breathing without worsen-
ing for 24 h. No COPD patient worsened after the withdrawal
of IPV. Also, we hadn't planned to evaluate IPV in patients
recovering from their acute exacerbation. Another limitation of
the trial was the small number of patients included. Further
studies are also needed to determine the mechanisms of
improvement with IPV in patients with acute exacerbations of
COPD.
Conclusion
This randomized controlled study shows that chest physiother-
apy by IPV may prevent the deterioration of acute exacerba-
tions of COPD with mild respiratory acidosis. The method we
employed was well tolerated. In addition, the technique per-
formed at an early stage could be a cost-saving measure. Fur-
ther studies are needed to determine the long term effects of
IPV and to clarify the impact of IPV in the management of
patients with acute exacerbations of COPD.
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